UP!

QDEL $150.21

QDEL target price
150.21
0
0
Quidel Corporation
Type
Public
Traded as NASDAQ: QDEL
Industry Pharmaceutical Industry
Founded 1979
Headquarters San Diego, California, United States
Key people
Douglas C. Bryant, President & CEO
Randall J. Steward, CFO
Products Diagnostic healthcare manufacturer
Website www.quidel.com

Quidel Corporation (Nasdaq: QDEL) is a major American manufacturer of diagnostic healthcare products that are sold worldwide.

Quidel commenced operations in 1979 and launched its first products in 1984. Quidel Corporation was formed in 1991 when Quidel and Monoclonal Antibodies merged.

On June 18, 1997 Quidel settled a lawsuit with Becton Dickinson. Quidel had been accused of infringing patents on Becton's strep and chlamydia products. Quidel agreed to buy a product license and pay royalties on its product sales.

In February 2004, Inverness Medical Innovations sued Quidel for patent infringement. That same month, Quidel countersued against Inverness.

Since its merger, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions.

Quidel's core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development.

Quidel's current products fall generally into these categories: (1) lateral flow, where it focuses on infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products.

These products include assays such as QuickVue, Thyretain and the new Sofia and AmpliVue brands, which focus on diagnosing influenza, thyroid disease and many other diseases and can improve the healthcare quality of hospitals.

During 2011, the US Food and Drug Administration (FDA) and the European Conformity Mark provided Quidel with 510(k) clearance for selling Sofia Analyzer, and another 510(k) clearance for the Quidel Molecular hMPV Assay.

In 1999, Quidel acquired Metra Biosystems, Inc.to participate in bone health assessment.In 2000, Quidel acquired Litmus Concepts, Inc., a privately held in vitro diagnostic company.

In 2010, Quidel acquired Diagnostic Hybrids, Inc. a privately held in vitro diagnostic company.In 2013, Quidel acquired BioHelix Corporation (BioHelix), established in 2004, and was to pay $10 million to te BioHelix shareholders.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q2 2021 2021-07-28 Future report Set alerts
Q1 2021 2021-05-06 4.38 4.38
Q4 2020 2021-02-18 11.07 11.07
Q3 2020 2020-10-29 0.00 0.00
Q2 2020 2020-07-30 1.86 1.55
Q1 2020 2020-05-07 1.22 0.93
Q4 2019 2020-02-12 1.00 0.71
Q3 2019 2019-10-30 0.70 0.38
Q2 2019 2019-08-08 0.36 0.03
Q1 2019 2019-05-08 0.91 0.60

Ratings

2016-06-13 Upgrade Raymond James Market Perform to Outperform $21.50
2016-06-13 Upgrade Raymond James Financial Inc. Market Perform to Outperform $21.50
2016-04-28 Reiterated Rating Canaccord Genuity Hold
2016-03-21 Reiterated Rating Canaccord Genuity Hold $17.00 to $18.00
2016-02-18 Lower Price Target Craig Hallum Hold $18.00 to $16.00
2016-02-18 Lower Price Target Barclays Overweight $28.00 to $22.00
2016-02-18 Lower Price Target Canaccord Genuity Hold $18.00 to $17.00
2016-02-18 Lower Price Target Barclays PLC Overweight $28.00 to $22.00
2016-02-09 Downgrade Canaccord Genuity Buy to Hold $22.00 to $18.00
2016-01-09 Reiterated Rating Piper Jaffray Buy
2016-01-09 Reiterated Rating Piper Jaffray Cos. Buy
2016-01-08 Downgrade William Blair Outperform to Market Perform
2016-01-08 Lower Price Target Canaccord Genuity Buy $25.00 to $22.00
2016-01-08 Lower Price Target Piper Jaffray Overweight $30.00 to $22.00
2015-12-14 Reiterated Rating Canaccord Genuity Buy $25.00
2015-12-14 Downgrade Raymond James Outperform to Market Perform
2015-11-01 Reiterated Rating Canaccord Genuity Buy $25.00
2015-10-29 Lower Price Target Raymond James $27.00 to $22.00
2015-10-23 Downgrade Craig Hallum Buy to Hold $32.00 to $18.00
2015-09-11 Reiterated Rating William Blair Buy
2015-09-02 Initiated Coverage Barclays Overweight $28.00
2015-07-29 Reiterated Rating Canaccord Genuity Buy $25.00
2015-07-23 Reiterated Rating Canaccord Genuity Buy $27.00
2015-06-12 Reiterated Rating Canaccord Genuity Buy $27.00
2015-04-26 Reiterated Rating Canaccord Genuity Buy $27.00
2015-02-12 Reiterated Rating Canaccord Genuity Buy $34.00 to $30.00
2014-12-18 Reiterated Rating William Blair Buy
2014-09-18 Reiterated Rating Piper Jaffray Buy
2014-07-23 Boost Price Target Raymond James Outperform $24.00 to $26.00
2014-07-23 Lower Price Target Canaccord Genuity Buy $28.00 to $26.00
2014-07-23 Reiterated Rating JPMorgan Chase & Co. Neutral $21.00 to $22.00
2014-07-23 Upgrade Wedbush Underperform to Neutral $18.00 to $20.00
2014-07-09 Initiated Coverage Wells Fargo & Co. Market Perform
2014-07-09 Initiated Coverage Wells Fargo Market Perform
2014-04-24 Lower Price Target Canaccord Genuity Buy $35.00 to $28.00
2013-12-18 Initiated Coverage JMP Securities Market Perform
2011-03-03 Downgrade Wedbush Outperform to Neutral $14 to $13
2010-05-27 Upgrade Wedbush Neutral to Outperform $15
2009-09-30 Initiated William Blair Mkt Perform
2009-09-11 Reiterated Wedbush Morgan Underperform $11 to $12
2009-08-06 Downgrade Wedbush Morgan Neutral to Underperform $11
2009-07-23 Reiterated Caris & Company Average $11 to $13
2009-07-20 Downgrade Caris & Company Above Average to Average $11
2009-06-08 Reiterated Wedbush Morgan Hold $10 to $11
2009-03-17 Reiterated CL King Strong Buy $22.50 to $12
2009-03-17 Reiterated Caris & Company Above Average $16 to $11
2009-03-16 Reiterated Wedbush Morgan Buy $16 to $12
2008-11-24 Reiterated CL King Strong Buy
2008-10-20 Upgrade Collins Stewart Hold to Buy
2008-09-05 Downgrade Lazard Capital Buy to Hold
2016-06-13 Upgrade Raymond James Market Perform to Outperform $21.50
2016-06-13 Upgrade Raymond James Financial Inc. Market Perform to Outperform $21.50
2016-04-28 Reiterated Rating Canaccord Genuity Hold
2016-03-21 Reiterated Rating Canaccord Genuity Hold $17.00 to $18.00
2016-02-18 Lower Price Target Craig Hallum Hold $18.00 to $16.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
SCHULER JACK W 9.95%  (3414053) AXDX / BIOL / GTXI / HNSN / MBLX / MDT / QDEL / SRCL / VRML /
BRYANT DOUGLAS C President & CEO 0.86%  (294313) QDEL /
Bujarski Robert Joseph SVP, General Counsel & Secy 0.14%  (46381) QDEL /
Brown Thomas D 0.13%  (45025) AXDX / CPHD / QDEL / SRCL /
Dammeyer Rodney F 0.12%  (42769) QDEL / SRCL /
BUECHLER KENNETH F 0.11%  (39147) QDEL / SQNM /
PULIDO MARK 0.10%  (35947) QDEL /
McLeod Scot M SVP - Operations 0.10%  (34486) QDEL /
STEWARD RANDALL J Chief Financial Officer 0.09%  (31790) QDEL /
TAMERIUS JOHN SVP - Clinical/Reg Affairs 0.07%  (24802) QDEL /
Stenzel Timothy Todd Chief Science Officer 0.05%  (18016) QDEL /
POLAN MARY LAKE PH D 0.05%  (16130) QDEL /
BORKAR RATAN S SVP, Intl Comm Operations 0.04%  (13134) QDEL /
Kroll Werner SVP, R&D 0.03%  (11348) QDEL /
SMITS MARK W SVP-Commercial Operations 0.03%  (9608) NEO / QDEL /
Russell Edward Keith SVP-Global Commercial Ops 0.03%  (8887) QDEL /
Abney Michael Donald Jr. SVP - Distribution 0.02%  (8557) QDEL /
WIDDER KENNETH J 0.02%  (5680) EVOK / QDEL /
SLACIK CHARLES P 0.01%  (2601) QDEL / SQNM / STAA /